Compare Merck & Co., Inc. (MRK) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Raymond James Financial, Inc. — how do they compare? Merck & Co., Inc. trades at $148.16 (market cap $363.98B), while Raymond James Financial, Inc. trades at $175.47 (market cap $33.75B). The key difference: Merck & Co., Inc. is far larger — about 10.8× Raymond James Financial, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.3%). Which is the better fit depends on your goals.
| MRK | RJF | |
|---|---|---|
Market Cap | $363.98B | $33.75B |
Sector | Health | Financials |
52-Week High | $156.43 | $181.18 |
52-Week Low | $77.60 | $140.89 |
Enterprise Value | $410.75B | — |
Dividend Yield | 2.3% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a mixed technical picture showing bearish overall signals but bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $3.14 beating estimates of $2.93, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Recent developments include dividend declarations and PGA TOUR sponsorship announcements.
RJF presents a balanced investment case with 44% analyst buy ratings and a $184.11 consensus price target offering 4.3% upside. Strengths include consistent earnings growth and wealth management expansion, while risks involve rising expenses and capital market volatility. The stock trades at reasonable valuations with P/E of 15.39 and P/S of 2.36, supported by 15.37% net margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
